

## EDITORIAL

# Contextual factors for prevention and management of obesity in India

Manya Prasad, Saraa Angel L, Vinamrata Kapoor Ghai, Keerthi, Saumya Vats, Umesh Kapil

All India Institute of Medical Sciences, New Delhi

### CORRESPONDING AUTHOR

Dr Umesh Kapil, Former Professor, Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences (AIIMS), New Delhi 110029

Email: [umeshkapil@gmail.com](mailto:umeshkapil@gmail.com)

### CITATION

Prasad M, Angel SL, Ghai VK, Keerthi, Vats S, Kapil U. Contextual factors for prevention and management of obesity in India. Journal of the Epidemiology Foundation of India. 2025;3(2):99-100.

DOI: <https://doi.org/10.56450/JEFI.2025.v3i02.001>

### ARTICLE CYCLE

Received: 14/06/2025; Accepted: 27/06/2025; Published: 30/06/2025

*This work is licensed under a Creative Commons Attribution 4.0 International License.*

©The Author(s). 2025 Open Access

When the Prime Minister recently described obesity as a 'silent crisis' for India, it elevated the issue from a clinical concern to a matter of national policy priority (1). Obesity is now widely recognized as a formidable public health challenge in India, with prevalence rising rapidly in both urban and rural settings. As of 2025, India is preparing its first national obesity guideline, aiming to shift the focus beyond global standards to a home-grown framework that accounts for prevention, early diagnosis, and culturally appropriate interventions (2).

A recurring theme in this discourse is whether lower BMI thresholds—such as  $\geq 23 \text{ kg/m}^2$  for overweight and  $\geq 25 \text{ kg/m}^2$  for obesity—should be formally adopted in place of the WHO's international cut-offs ( $\geq 25$  and  $\geq 30$ , respectively).

**The cut-off debate:** While several expert consensus statements and smaller studies support the use of lower thresholds for Asian Indians, the evidence remains fragmented. Some cross-sectional studies suggest that cardiometabolic risk factors, including diabetes and hypertension, cluster at BMI levels well below  $30 \text{ kg/m}^2$  (3). Yet, large-scale cohort data directly linking these lower cut-offs with incident cardiovascular events and mortality in Indian populations are still limited. As such, the question of optimal thresholds remains open and could be a focus of systematic research rather than a settled matter.

**Broader contextual factors:** The cut-off issue is only one dimension of contextualisation. India's unique "thin-fat" phenotype, characterised by higher body fat percentage and visceral adiposity at lower BMI, points to the need for greater emphasis on waist circumference and waist-to-height ratio as markers of risk. Equally, cultural dietary patterns—from carbohydrate-heavy staples to fasting traditions—shape both the epidemiology of obesity and the feasibility of interventions.

Physical activity recommendations must also be contextualised. While international guidelines emphasise structured exercise, the Indian reality is often one of limited public space, gender barriers, and reliance on informal physical activity. Indigenous practices like yoga offer a promising, culturally acceptable avenue, but require more rigorous evaluation for long-term weight and metabolic outcomes.

**Health Systems readiness and feasibility:** 'Evidence to decision' factors such as values and preferences of Indian patients, feasibility within our health system, cultural acceptability, equity, and resource use are critical to ensure that recommendations are not only evidence-based but also implementable. Even the most scientifically sound guidelines must consider health system capacity and equity. Pharmacotherapy and bariatric surgery, central features of many international guidelines, remain inaccessible for most Indians due to cost,

availability, and limited specialist infrastructure. In contrast, scalable strategies—such as community-based counselling, school interventions, and integration with the NP-NCD framework—may offer more sustainable impact, but remain under-researched.

**Lessons from International Guidelines:** Guidelines such as NICE (UK), CMAJ (Canada) and the American Gastroenterological Association (AGA)(4-9) provide recommendations on behavioural therapy, diet, physical activity, pharmacotherapy, and bariatric surgery, some of which can be adopted and adapted to the Indian context (Table 1). However, they often assume resource availability, health insurance coverage, and multidisciplinary teams—conditions not always feasible in India. Cost, feasibility, and cultural acceptability receive limited attention. Importantly, international guidelines do not

address the “thin–fat” phenotype or proposed South Asian anthropometric cut-offs.

**Moving Forward:** In short, while global guidelines provide a foundation, their direct transplantation to India risks missing key contextual factors. The cut-off debate, highlighted by recent policy discussions and media coverage, is emblematic of the broader need to generate high-quality Indian evidence—from prospective cohort studies to implementation research.

Developing obesity guidelines for India should therefore be seen not as a one-time exercise of adopting international guidelines, but as an ongoing process of adapting global evidence, testing assumptions, and incorporating local realities. Only then can India arrive at definitions and recommendations that are both scientifically credible and practically feasible.

**Table 1: Coverage of specific contexts in international guidelines on obesity**

Guideline (Year)	Anthropometry (BMI/WC/WHtR)	Metabolic risk & comorbidities	Thin–Fat / central obesity	Resource constraints	Pharmacotherapy / surgery
<b>NICE NG246 (UK, 2025)</b>	BMI + WC + WHtR; ethnic risk noted	Strong focus on DM, HTN, CVD, NAFLD, OSA	Acknowledges South Asian risk	Community cost-effectiveness; not LMIC-specific	Full pathway for meds + surgery
<b>AGA Pharmacotherapy (USA, 2022)</b>	BMI $\geq$ 30 or $\geq$ 27 + comorbidities	Comorbidities guide drug use	Not covered	Mentions cost but not LMIC	Pharmacotherapy focus
<b>CMAJ Adults (Canada, 2020)</b>	BMI + WC + Edmonton staging	Detailed labs + comorbidity screening	Recognises adiposity at lower BMI	Acknowledges variation in resources	Recommends meds + surgery
<b>CMAJ Children (Canada, 2022)</b>	BMI z-scores + WC	Screening BP, HbA1c, lipids, ALT	Normal BMI + adiposity flagged	Considers family/cost barriers	Meds limited; surgery in select adolescents

## REFERENCES

1. PM Modi warns against rising obesity, highlights need to adopt healthier lifestyles. DD News. 2025 Aug 15. Available from: <https://ddnews.gov.in/en/pm-modi-warns-against-rising-obesity-highlights-need-to-adopt-healthier-lifestyles/#:~:text=In%20his%20Independence%20Day%20address,in%20lifestyle%20and%20detary%20habits>
2. Sharma M. After PM's 'silent crisis' warning, India drafts first obesity guidelines. India Today. 2025 Aug 26. Available from: <https://www.indiatoday.in/health/story/india-national-obesity-guideline-rising-obesity-management-prevention-2776806-2025-08-26>
3. Misra A, Vikram NK, Ghosh A, Ranjan P, Gulati S; India Obesity Commission Members. Revised definition of obesity in Asian Indians living in India. *Diabetes Metab Syndr*. 2025 Jan;19(1):102989.
4. National Institute for Health and Care Excellence. Obesity: identification, assessment and management [NICE guideline NG246]. London: NICE; 2025.
5. Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, et al. Obesity in adults: a clinical practice guideline. *CMAJ*. 2020;192(31):E875–91.
6. Robinson E, Mazurak VC, Buchholz A, Ho J, Chaput J-P, Drouin-Chartier J-P, et al. Clinical practice guideline on the management and treatment of obesity in children and adolescents in Canada. *CMAJ*. 2022;194(10):E338–54.
7. Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM, et al. AGA Clinical Practice Guideline on pharmacological interventions for adults with obesity. *Gastroenterology*. 2022;163(5):1198–225.
8. Younossi ZM, Corey KE, Lim JK. AGA Clinical Practice Update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review. *Gastroenterology*. 2021;160(3):912–8.
9. Muniraj T, Day LW, Teigen LM, Ho EY, Sultan S, Davitkov P, et al. AGA Clinical Practice Guidelines on intragastric balloons in the management of obesity. *Gastroenterology*. 2021;160(5):1799–808.